Last reviewed · How we verify
Pirfenidone Capsules（600mg）
Antifibrotic agent
Antifibrotic agent Used for Idiopathic pulmonary fibrosis.
At a glance
| Generic name | Pirfenidone Capsules（600mg） |
|---|---|
| Sponsor | Beijing Continent Pharmaceutical Co, Ltd. |
| Drug class | Antifibrotic |
| Target | TGF-β |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
Pirfenidone is a small molecule that inhibits the production of transforming growth factor-beta (TGF-β), a key cytokine involved in fibrosis.
Approved indications
- Idiopathic pulmonary fibrosis
Common side effects
- Cough
- Dyspnea
- Fatigue
Key clinical trials
- Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia (PHASE2, PHASE3)
- Pirfenidone Treat Myocardial Fibrosis After Acute Myocardial Infarction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pirfenidone Capsules（600mg） CI brief — competitive landscape report
- Pirfenidone Capsules（600mg） updates RSS · CI watch RSS
- Beijing Continent Pharmaceutical Co, Ltd. portfolio CI